艾媒咨询|2021年中国养生美容市场研究报告

2021年9月4日，“2021CIBE中国养生美容大会”将在广州•广交会展馆举办。大会以“养生•美容”为主题，从养生行业的发展现状及未来趋势出发，探索养生与美容行业间的平衡，挖掘养生美容高级且特色的项目，拓宽美业增量赛道的选择，构建养生美容的全渠道触点，汇聚平台、品牌、优质连锁、行业专家等嘉宾共同探讨推动行业的发展与进步。如今美业的竞争不仅是产品服务的竞争，更是大数据的比拼。艾媒咨询CEO兼首席分析师张毅受邀出席本次大会并将现场发布《2021年中国养生美容市场研究报告》，将利用艾媒大数据决策和智能分析系统的数据挖掘结果，洞察消费者需求和中国养生美容市场现状。
On September 4, 2021, "2021cibe China Health and beauty conference" will be held in the exhibition hall of Guangzhou • Canton Fair. With the theme of "health preservation and beauty", starting from the development status and future trend of the health preservation industry, the conference explores the balance between health preservation and beauty industry, excavates advanced and characteristic projects of health preservation and beauty, widens the choice of incremental tracks of the beauty industry, constructs all-channel contacts of health preservation and beauty, and gathers platforms, brands, high-quality chains Industry experts and other guests discussed and promoted the development and progress of the industry.Today, the competition of the US industry is not only the competition of products and services, but also the competition of big data. Zhang Yi, CEO and chief analyst of AI media consulting, was invited to attend the conference and will release the Research Report on China's health and beauty market in 2021. He will use the data mining results of AI media's big data decision-making and intelligent analysis system to gain insight into consumer demand and the current situation of China's health and beauty market.

鲁抗医药2021年第三季度报告

艾媒咨询｜2022-2023年全球与中国抗衰老行业发展及消费者需求研究报告

抗衰老的概念兴起于国外，指人们希望能够在寿命延长的同时能够“健康衰老”。iiMedia Research（艾媒咨询）数据显示，全球抗衰老市场规模已从2015年的1395亿美元增长至2021年的2160亿美元。

艾媒咨询 | 2024年全球及中国抗衰老市场环境分析与消费行为分析报告

随着中国消费者健康意识的觉醒以及“她经济”的崛起，消费者愈发重视抗衰老的相关产品。在消费结构升级、审美观念和悦己意识增强等多种因素的推动下，中国抗衰老市场消费持续增长。全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2024年全球及中国抗衰老市场环境分析与消费行为分析报告》数据显示，2014至2023年，中国大健康产业营收从2.5万亿元稳步增长至8.6万亿元，年均增长率显著。这一上升趋势反映了健康产业的快速发展和市场潜力。
艾媒咨询分析师认为，抗衰老已成为大部分中国消费者普遍关心的话题，市场对抗衰老产品和服务的需求较大。
With the awakening of Chinese consumers' health awareness and the rise of "her economy", consumers are paying more attention to anti-aging related products. Driven by multiple factors such as the upgrading of consumption structure, the enhancement of aesthetic concept and self-pleasing consciousness, the consumption of China's anti-aging market continues to grow. According to the latest "2024 Global and China Anti-aging Market Environment Analysis and Consumer Behavior Analysis Report" released by iiMedia Research, a third-party data mining and analysis institution in the global new economy industry, from 2014 to 2023, the revenue of China's big health industry has grown steadily from 2.5 trillion yuan to 8.6 trillion yuan. The average annual growth rate is remarkable. This upward trend reflects the rapid development and market potential of the health industry.
Analysts from iiMedia Consulting believe that anti-aging has become a topic of general concern for most Chinese consumers, and the market has a large demand for anti-aging products and services.

艾媒咨询|2021年中国医美机构市场竞争态势及企业营销模式分析报告

本报告研究涉及企业/品牌/案例：华韩整形，瑞丽医美，美莱整形，医思健康

数据显示，2016—2020年中国医美行业市场规模五年平均增长率为12.8%，与此同时，中国医美市场用户规模增长了4倍多。在人们生活水平的提升、年轻一代对医美的接受度的提高、政府监管层对医美行业的整治给医美消费者信心的提升的综合作用下，预计中国医美市场规模在2022年将达到2232亿元。随着医美产品及仪器技术水平提升、医美知识普及等，民众对整形美容的观念正在向积极态度转变，在整个行业扩张的过程中，轻医美的受众面广、门槛低、复购率高，更有可能提升市场整体渗透率，成为我国医美行业的主要增量市场。
According to the data, from 2016 to 2020, the five-year average growth rate of the market scale of China's medical and American industry was 12.8%. At the same time, the user scale of China's medical and American market increased by more than four times. Under the combined effect of the improvement of people's living standards, the improvement of the acceptance of medical beauty by the younger generation, the regulation of the medical beauty industry by the government regulators and the improvement of medical beauty consumer confidence, it is expected that the scale of China's medical beauty market will reach 223.2 billion yuan in 2022. With the improvement of the technical level of medical beauty products and instruments and the popularization of medical beauty knowledge, people's concept of plastic beauty is changing to a positive attitude. In the process of the expansion of the whole industry, light medical beauty has a wide audience, low threshold and high repurchase rate, which is more likely to improve the overall penetration rate of the market and become the main incremental market of China's medical beauty industry.

艾媒咨询|2021年中国化妆品用户调研与发展预判研究报告

本报告研究涉及企业/品牌/案例：上海家化，欧莱雅，完美日记

2021年5月31日，全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research (艾媒咨询) 发布《2021年中国化妆品用户调研与发展预判研究报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据，对中国化妆品产业进行了全面分析，并分别对护肤品和美妆进行了超过2000名的用户调研，并提出了趋势预判。
On May 31, 2021, iiMedia Research, a world-renowned third-party data mining and analysis organization for the new economy industry, released the "2021 China Cosmetics User Survey and Development Pre-judgment Research Report." Based on the basic data of iiMedia Data Center, iiMedia Consulting Business Intelligence Database, and iiMedia Business Opinion and Public Opinion Data Monitoring System, the report conducted a comprehensive analysis of the Chinese cosmetics industry, and conducted a survey of more than 2,000 users of skincare and beauty products. Propose trend prediction.

艾媒咨询｜2024-2025年中国美妆行业发展现状与消费趋势报告

随着中国消费者文化自信意识的觉醒以及数字化经济的加速演进，国产化妆品品牌初步具备了与国际化妆品品牌抗衡的规模。在消费结构升级、审美观念和悦己意识增强等多种因素的推动下，国内化妆品消费持续增长。全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2024-2025年中国美妆行业发展现状与消费趋势报告》数据显示，2024年中国消费者在购买化妆品时，最关注的因素是产品成分（58.8%）和产品功效（41.4%）；超三成的消费者认为化妆品存在的主要问题是产品说明模糊和化妆品功效持续时间短。随着短视频平台的兴起，化妆品市场规模不断扩大，消费者需求也在不断变化。未来，中国化妆品行业市场仍然具有巨大的发展潜力。
With the awakening of Chinese consumers' cultural self-confidence and the accelerated evolution of digital economy, domestic cosmetics brands have initially possessed the scale to compete with international cosmetics brands. Driven by many factors such as the upgrading of consumption structure, the enhancement of aesthetic concept and self-pleasing consciousness, domestic cosmetics consumption continues to grow. According to the latest Research Report on the development status and consumption trend of China's beauty industry from 2024 to 2025 released by iiMedia Research, a third party data mining and analysis institution in the global new economy industry, Chinese consumers will buy cosmetics in 2024. The most concerned factors were product composition (58.8%) and product efficacy (41.4%). More than 30% of consumers believe that the main problems with cosmetics are vague product descriptions and the short duration of cosmetic efficacy. With the rise of short video platforms, the size of the cosmetics market continues to expand, and consumer demand is constantly changing. In the future, China's cosmetics industry market still has huge potential for development.

艾媒咨询｜2024年中国防晒化妆品行业消费趋势洞察研究报告

防晒不仅关乎肌肤健康，更是预防光老化、抵御皮肤癌等严重肌肤问题的关键措施，其重要性在现代美容护肤领域日益凸显。全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2024年中国防晒化妆品行业消费趋势洞察研究报告》数据显示，中国防晒化妆品市场呈现出稳健增长态势，2023年市场规模已达148亿元，且预计到2028年将进一步扩容至224亿元。消费者对防晒化妆品的期待日益精细化和多元化，iiMedia Research（艾媒咨询）调研数据显示，消费者最关注产品的长效防护能力（71.4%），以及功效的细分化和专业化（47.0%）。中国防晒化妆品市场在户外消费热潮、消费者对长效防护与精细化护肤需求的双重驱动下持续扩大，未来将沿着精准防晒和个性化定制的路径深度发展，以多元化、多功能的产品创新迎合消费者日益提升的护肤期望与审美标准。
Sun protection is not only related to skin health, but also a key measure to prevent photoaging and prevent serious skin problems such as skin cancer, and its importance is increasingly prominent in the field of modern beauty and skin care. According to the latest "Insights on Consumption Trends in China's Sunscreen Cosmetics Industry in 2024" released by iiMedia Research, a third-party data mining and analysis institution in the global new economy industry, China's sunscreen cosmetics market has shown a steady growth trend, and the market size has reached 14.8 billion yuan in 2023. And it is expected to further expand to 22.4 billion yuan by 2028. Consumers' expectations for sunscreen cosmetics are increasingly refined and diversified. According to iiMedia Research's survey data, consumers are most concerned about the long-term protection ability of products (71.4%), as well as the segmentation and specialization of efficacy (47.0%). Driven by the boom in outdoor consumption and consumers' demand for long-term protection and refined skin care, China's sunscreen cosmetics market will continue to expand along the path of precision sunscreen and personalized customization in the future, and cater to consumers' increasing skin care expectations and aesthetic standards with diversified and multi-functional product innovation.

艾媒咨询 | 2025年中国医美行业发展状况与消费行为调查数据

随着消费升级与技术迭代，中国医美行业已从传统整形扩展至轻医美、抗衰老等多元化领域，市场规模持续扩大。根据全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国医美行业发展状况与消费行为调查数据》显示，2025年中国医美服务行业市场规模为3701亿元，2025年中国轻医美市场用户规模达3105万人。中国医美市场的增长不仅源于消费升级，也得益于技术普惠与轻医美项目的高复购率。当前行业已进入以精细化运营、差异化服务和合规化发展为核心驱动的新阶段。
在2025年中国消费者对医美项目的接受程度中，“会考虑整形，但风险要相对可控”位列第一，占比46.02%；其次是“能够接受手术医美整形，并承受一定风险”，占比22.94%。此外，在消费者接受过的医美项目中，轻医美（非手术类）占比最高，达到74.45%；医美整形（手术类）的占比为33.52%。这表明中国消费者对医美的态度趋于理性与谨慎，安全可控的非手术类项目成为市场主流偏好。同时，手术类项目亦拥有稳定的需求群体，显示出市场需求的层次性与多元化。
艾媒咨询分析师认为，未来中国医美市场将延续“轻医美主导、技术驱动、合规深化”的主线发展。一方面，非手术项目凭借低风险、高复购优势，仍是增长核心，Z世代与男性、下沉市场需求进一步释放。另一方面，再生材料、AI个性化方案及智能器械加速迭代，推动服务精准化与效果革新。此外，监管常态化下，行业加速品牌化整合，合规机构与上游技术型企业凸显优势。总的来说，消费者更趋理性，追求自然效果与安全保障，倒逼市场从营销竞争转向以品质、精细化运营为核心的高质量发展新阶段。
With the upgrading of consumption and technological advancements, China's medical aesthetics industry has expanded from traditional plastic surgery to diversified fields such as minimally invasive aesthetics and anti-aging. The market size has continued to grow. According to the latest "2025 China Medical Aesthetics Industry Development Status and Consumer Behavior Survey Data" released by iiMedia Research, a leading third-party data mining and analysis institution for the new economy industry, the market size of China's medical aesthetics service industry will reach 370.1 billion yuan in 2025, and the user scale of the minimally invasive aesthetics market in China will reach 31.05 million people in 2025. The growth of China's medical aesthetics market is not only due to the upgrading of consumption but also benefits from the popularization of technology and the high repurchase rate of minimally invasive aesthetics projects. Currently, the industry has entered a new stage driven by refined operation, differentiated services, and compliance development.
In terms of Chinese consumers' acceptance of medical aesthetics projects in 2025, "Would consider plastic surgery, but the risk should be relatively controllable" ranks first, accounting for 46.02%; followed by "Can accept surgical medical aesthetics and bear certain risks", accounting for 22.94%. Additionally, among the medical aesthetics projects consumers have received, minimally invasive aesthetics (non-surgical) accounts for the highest proportion, reaching 74.45%; surgical medical aesthetics accounts for 33.52%. This indicates that Chinese consumers' attitudes towards medical aesthetics are becoming more rational and cautious, and non-surgical projects with low risks and high repurchase rates have become the mainstream preference in the market. At the same time, surgical projects also have a stable demand group, demonstrating the hierarchical and diversified nature of market demand.
Analysts from iiMedia Research believe that in the future, China's medical aesthetics market will continue to develop along the main line of "minimally invasive aesthetics dominance, technology-driven, and compliance deepening". On the one hand, non-surgical projects, with their low-risk and high-repurchase advantages, will remain the core of growth, and the demands of Generation Z, men, and consumers in lower-tier cities will be further released. On the other hand, regenerative materials, AI personalized solutions, and intelligent devices will accelerate iteration, promoting the precision and effect innovation of services. Moreover, under the normalization of regulation, the industry will accelerate brand integration, and compliant institutions and upstream technology enterprises will highlight their advantages. In summary, consumers are becoming more rational, pursuing natural effects and safety guarantees, which will force the market to shift from marketing competition to high-quality development centered on quality and refined operation.

艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告

本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业

随着生物医药技术不断突破，中国生物医药产业快速发展，2018年，单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元，实现同比增长。iiMedia Research(艾媒咨询)监测发现，生物医药产业网络言值指数为49.7，网民评价态度偏向正面，上海网民对生物医药产业的关注度最高。未来，随着中国生物医药行业上市公司数量增多，行业与企业间竞争将更加激烈。

The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.